Dipal Doshi, President and CEO at Entrada Therapeutics, Inc. (TRDA), sold 14,040 shares at $15.04 ($213K) on 2022-09-27, disclosed to the SEC on 2022-09-28.
Open-market sale of $213k TRDA by President and CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $15.22 | 2,795 | $43K | 19.9% |
| 2 | $16.30 | 288 | $5K | 2.2% |
| 3 | $15.04 | 3,453 | $52K | 24.3% |
| 4 | $15.04 | 3,453 | $52K | 24.3% |
| 5 | $15.82 | 966 | $15K | 7.2% |
| 6 | $15.23 | 3,085 |
| $47K |
| 22.0% |
| Total | $15.20 avg | 14,040 | $213K | 100% |
| Filing → |
| TRDA | SELL | 2024-05-20 | $45K | — | Filing → |
| TRDA | SELL | 2024-02-20 | $15K | — | Filing → |
| TRDA | SELL | 2024-01-18 | $16K | — | Filing → |